In breast cancer (DCIS), both oncostatin M (OSM) and interleukin-6 (IL-6) have been proposed to regulate the expression and activity of S100A7 by regulating PI3K, STAT3 and Erk signaling [38]. This evidence concerns the gene IL6 and breast cancer.